Meeting
2024 ASCO Genitourinary Cancers Symposium
Association of body-mass index (BMI) with age, PSA, and survival in metastatic prostate cancer.
Authors
Martin W. Schoen
St. Louis Veterans Affairs Medical Center, St. Louis, MO
Martin W. Schoen , Robert Bruce Montgomery , Saira Khan , Daniel B. Eaton Jr., Nicholas Fedele , Ashwin Sachdeva , Andrew Warren Hahn , Ruth Douglas Etzioni
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 96)
DOI
10.1200/JCO.2024.42.4_suppl.96
Abstract #
96
Poster Bd #
D11
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Comparison of outcomes with docetaxel or ARPI combination therapy for metastatic hormone-sensitive prostate cancer (mHSPC) by volume of disease.
First Author: Martin W. Schoen
Poster
2023 ASCO Genitourinary Cancers Symposium
Frailty and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
First Author: Ekamjit Singh Deol
Poster
2022 ASCO Genitourinary Cancers Symposium
Predictive factors for effectiveness from novel androgen-receptor-axis-targeted agents in patients with metastatic prostate cancer.
First Author: Koshiro Nishimoto
Poster
2021 ASCO Annual Meeting
Radium-223 (Ra-223) versus novel antihormone therapy (NAH) for progressive metastatic castration-resistant prostate cancer (mCRPC) after 1 line of NAH: RADIANT, an international phase 4, randomized, open-label study.
First Author: Karim Fizazi